Consistent Clinical Benefit of Giredestrant Across the Menopausal Spectrum in ER+/HER2− Early Breast Cancer
- Home
- asco conference 2026
- giredestrant serd lidera bc phase3 er positive her2 negative early breast cancer
Reducing Metastatic Recurrence Across Menopausal Subgroups with Giredestrant in ER+/HER2− Early Breast Cancer
Giredestrant is a next-generation oral selective estrogen receptor degrader (SERD) being evaluated as adjuvant endocrine therapy for ER+/HER2− early breast cancer. In the Phase III lidERA BC trial, a subgroup analysis by menopausal status demonstrated that giredestrant improved invasive disease free survival and distant recurrence free interval versus standard endocrine therapy in both premenopausal and postmenopausal patients. Notably, giredestrant reduced the risk of metastatic recurrence by 42% and 24% in premenopausal and postmenopausal patients, respectively. The treatment also showed favorable tolerability, with fewer discontinuations and lower rates of musculoskeletal pain related discontinuations than aromatase inhibitors, supporting its potential as a new adjuvant endocrine treatment option across menopausal subgroups.
The US FDA has granted Priority Review to the NDA for giredestrant in ER-positive, HER2-negative Stage I–III breast cancer, with a PDUFA target action date of November 30, 2026.
|
Efficacy Outcomes of the Phase III lidERA Breast Cancer Study | ||||
|
Endpoint |
Premenopausal (Giredestrant) (n=849) |
Premenopausal (SOC ET) (n=838) |
Postmenopausal (Giredestrant) (n=1220) |
Postmenopausal (SOC ET) (n=1236) |
|
IDFS Hazard Ratio (HR) |
0.65 |
Reference |
0.74 |
Reference |
|
3-Year IDFS Rate (%) |
94 |
91.5 |
91.3 |
88.3 |
|
DRFI Hazard Ratio (HR) |
0.58 |
Reference |
0.76 |
Reference |
|
3-Year DRFI Rate (%) |
95.5 |
92.6 |
93.6 |
91.6 |
|
DRFI, distant recurrence-free interval; IDFS, invasive disease-free survival; SOC ET, standard-of-care endocrine therapy | ||||
|
Safety Outcomes of the Phase III lidERA Breast Cancer Study | ||||||||
|
Safety Endpoint (%) |
PRE-M Giredestrant (n=840) |
PRE-M SOC ET (n=832) |
SOC ET (AI) n = 563 |
SOC ET (TAM) n = 269 |
POST-M Giredestrant (n=1209) |
POST-M SOC ET (n=1231) |
SOC ET (AI) n = 1183 |
SOC ET (TAM) n = 48 |
|
All-Grade / Grade 3–4 AEs |
95.5/18.2 |
95.3/17.3 |
96.3/16.9 |
93.3/18.2 |
94.5/20.7 |
93.7/18.4 |
94.1/18.6 |
85.4/14.6 |
|
AE leading to tx discontinuation |
4.9 |
7.8 |
7.5 |
8.6 |
5.7 |
8.5 |
8.2 |
16.7 |
|
Musculoskeletal pain |
58.1 |
53.5 |
59.7 |
40.5 |
50.8 |
53.6 |
54.6 |
29.2 |
KOL insights
“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest.” –Expert Opinion
“In early ER-positive breast cancer, challenges with disease recurrence and treatment adherence mean there is an urgent need for more effective, tolerable endocrine therapies.”–Expert Opinion
Conclusion
Breast cancer is the most common cancer among women in the United States. The United States accounts for approximately ~44% of the 7MM prevalent HR+ breast cancer population.
In the ER+/HER2− early breast cancer treatment landscape, aromatase inhibitors and tamoxifen remain the standard adjuvant endocrine therapies despite ongoing risks of disease recurrence and treatment discontinuation. The Phase III lidERA BC subgroup analysis demonstrated that giredestrant improved invasive disease-free survival (IDFS) and reduced distant recurrence risk across both premenopausal and postmenopausal populations, while showing lower treatment discontinuation rates than standard endocrine therapy. These findings, together with the recent FDA Priority Review acceptance of giredestrant, underscore its potential to become the first oral SERD approved for the adjuvant treatment of ER+/HER2− early breast cancer. As competition intensifies among next-generation endocrine therapies and emerging oral SERDs, giredestrant's positive Phase III data and favorable tolerability profile position it as a promising entrant in the evolving ER+/HER2− early breast cancer landscape.
Executive Summary
Phase III lidERA BC subgroup analysis demonstrated that giredestrant improved invasive disease free survival and reduced the risk of distant recurrence versus standard endocrine therapy in both premenopausal and postmenopausal patients with ER+/HER2− early breast cancer. Notably, giredestrant reduced the risk of metastatic recurrence by 42% in premenopausal patients and 24% in postmenopausal patients, while also showing lower treatment discontinuation rates and fewer musculoskeletal pain related discontinuations.